{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:43:23Z","timestamp":1761896603062},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejim.2017.07.033","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T07:00:15Z","timestamp":1502089215000},"page":"e42-e44","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?"],"prefix":"10.1016","volume":"44","author":[{"given":"Audrey","family":"Benyamine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Granel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.07.033_bb0005","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI116343","article-title":"Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis","volume":"91","author":"Kuwana","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2017.07.033_bb0010","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2017.07.033_bb0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/art.38219","article-title":"Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis","volume":"66","author":"Sobanski","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ejim.2017.07.033_bb0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejim.2010.01.004","article-title":"Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma","volume":"21","author":"Faucher","year":"2010","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2017.07.033_bb0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/rheumatology\/ken201","article-title":"Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA","volume":"47","author":"Parker","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.ejim.2017.07.033_bb0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2011.569753","article-title":"Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort","volume":"40","author":"Emilie","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ejim.2017.07.033_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.090677","article-title":"Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study","volume":"37","author":"Meyer","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2017.07.033_bb0040","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2017.07.033_bb0045","first-page":"373","article-title":"Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis","volume":"25","author":"Codullo","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2017.07.033_bb0050","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/art.22043","article-title":"Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I\/III antibodies","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051730300X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051730300X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T18:24:06Z","timestamp":1535567046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051730300X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":10,"alternative-id":["S095362051730300X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.033","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}